Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CG Oncology Inc.

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces Pricing of Public Offering
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Tickers CGON
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.